Epistemic AI

Epistemic AI is a platform that harnesses artificial intelligence (AI) and natural language processing (NLP) technologies to power applications in the pharmaceutical and life sciences industries. Its core offering is a knowledge platform that integrates and summarizes information from multiple public and proprietary sources, providing explainable insights to support data-driven decision-making processes.

Epistemic AI's initial application focused on enabling biopharmaceutical companies and regulators to collect, characterize, and evaluate sources of safety signals for drug safety monitoring. The platform's capabilities extend to accelerating biomedical research by connecting the dots across various disciplines within the life sciences, revealing underlying relationships among disease, diagnosis, treatment, and biological functions.

In June 2023, Epistemic AI unveiled its breakthrough generative AI solution, EpistemicGPT, designed specifically for life science professionals. This state-of-the-art AI platform employs large language models (LLMs) in conjunction with Epistemic AI's highly curated and trusted 6+ billion node knowledge graph. EpistemicGPT empowers researchers to interact with complex biomedical data in an unprecedented manner, providing complete, correct, and referenced insights from biomedical knowledge.

EpistemicGPT not only serves as a tool for finding information through chat-based queries but also enables users to test hypotheses, optimize trial planning, create market landscape reports, and investigate regulatory approvals within minutes. By combining LLMs with trusted biomedical data, EpistemicGPT addresses the acute market need for immediate access to accurate and reliable biomedical information.

Key customers and partnerships

In July 2022, Epistemic AI announced a strategic collaboration with Cincinnati Children's Hospital Medical Center through the Boomer Esiason Foundation (BEF). The Cincinnati Children's Division of Pulmonary Medicine utilizes the Epistemic AI platform to augment and accelerate their research in cystic fibrosis (CF) and respiratory disease. This collaboration, facilitated by BEF's venture philanthropy initiative, aims to provide clinical researchers with advanced tools to access CF-related knowledge in basic research, clinical trials, treatments, and existing research on rare genetic mutations and pathogens.

The partnership between BEF and Epistemic AI, initiated in 2020, is an ongoing effort to improve access to information using AI for the CF community. This collaboration enables Epistemic AI to work with foundations, companies, and hospitals, fostering a consortium of knowledge discovery to advance and expedite CF-related discoveries.